Back to top
more

GW Pharmaceuticals PLC (GWPH)

(Delayed Data from NSDQ)

$175.50 USD

175.50
434,163

+2.34 (1.35%)

Updated May 3, 2019 04:00 PM ET

After-Market: $175.65 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Better trading starts here.

Zacks News

New Strong Sell Stocks for May 6th

OYST, CDAY, GWPH, HRTG, and NATI have been added to the Zacks Rank #5 (Strong Sell) List on May 6, 2021

Jazz Pharma (JAZZ) Q1 Earnings Beat, Sales Miss, Stock Down

Jazz Pharmaceuticals (JAZZ) reports mixed first-quarter 2021 results as earnings beat estimates while sales miss the same. Shares down

JAZZ's Xywav sNDA for Hypersomnia Gets FDA Priority Review

JAZZ focuses on expanding label of its recently approved sleep drug, Xywav - a low sodium-formulation of Xyrem.

Neena Mishra headshot

Best Performing ETFs of Q1 2021

We highlight top performing ETF areas of the first quarter

Sweta Killa headshot

Inside the Top-Performing ETFs of Q1

Amplify Seymour Cannabis ETF (CNBS) topped the list of the best-performing ETFs of February with impressive returns of about 60%.

Jazz's (JAZZ) Vyxeos Gets FDA Nod for Pediatric Leukemia

Jazz Pharmaceuticals (JAZZ) gets FDA approval for label expansion of its cancer drug, Vyxeos, in pediatric patients with newly-diagnosed therapy-related acute myeloid leukemia.

Jazz Pharma (JAZZ) Q4 Earnings Miss, 2021 Sales View Dull

Jazz Pharmaceuticals (JAZZ) reports mixed fourth-quarter 2020 results as earnings miss estimates while sales beat the same. Shares down.

Neena Mishra headshot

Should You Invest in Marijuana Stocks & ETFs Now?

CNBC's cannabis expert Tim Seymour discusses the outlook for the industry.

Cannabis Stocks Rise on Hopes of Federal Legalization in US

Cannabis stocks seem poised to gain on hopes of removal of the federal ban on cannabis products under the new administration.

Sweta Killa headshot

Cannabis ETFs Spike on Jazz-GW Pharma Deal

Jazz Pharmaceuticals (JAZZ) agreed to buy cannabinoid drug company GW Pharmaceuticals (GWPH) for $7.2 billion in cash and stock that has strengthened the bullish case for the cannabis industry.

Sweta Killa headshot

Top ETF of November & Its Best Stocks

Amplify Seymour Cannabis ETF (CNBS) topped the list of the best-performing ETFs of November with impressive returns of more than 47%.

Neena Mishra headshot

Should You Buy Cannabis Stocks & ETFs Now?

CNBC's cannabis expert Tim Seymour discusses the recent developments in the space.

Neena Mishra headshot

Why Cannabis Stocks & ETFs Are Soaring

Marijuana stocks are rising on hopes of favorable regulatory environment

DENTSPLY SIRONA (XRAY) to Post Q3 Earnings: What's in Store?

DENTSPLY SIRONA's (XRAY) third-quarter results are likely to reflect weak segmental performance.

AmerisourceBergen (ABC) to Post Q4 Earnings: What's in Store?

AmerisourceBergen's (ABC) fiscal fourth-quarter results are likely to reflect solid performance at Pharmaceutical Distribution and Other units.

Why Earnings Season Could Be Great for GW Pharmaceuticals (GWPH)

GW Pharmaceuticals (GWPH) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Invitae (NVTA) to Report Q3 Earnings: What's in the Cards?

Invitae's (NVTA) genetic testing business is expected to have gained from expansion of biopharma partnerships in Q3.

McKesson (MCK) to Post Q2 Earnings: What's in the Offing?

McKesson's (MCK) fiscal second-quarter results are likely to reflect solid show by U.S. Pharmaceutical and Specialty Solutions segment.

OPKO Health (OPK) to Report Q3 Earnings: What's in Store?

OPKO Health's (OPK) third-quarter results are likely to reflect solid performance from Products segment and RAYALDEE.

Livongo Health (LVGO) to Post Q3 Earnings: What's in Store?

Livongo Health's (LVGO) third-quarter results are likely to reflect growth in core Livongo for Diabetes solution.

Baxter (BAX) to Report Q3 Earnings: What's in the Cards?

Baxter's (BAX) third-quarter performance is likely to reflect growth in its Acute Therapies business.

Stryker (SYK) to Report Q3 Earnings: What's in the Cards?

Stryker's (SYK) third-quarter results are likely to reflect weak segmental performances at Medsurg, Orthopaedic and Neurotechnology & Spine.

Trina Mukherjee headshot

What's in Store for Meridian Bioscience's (VIVO) Q3 Earnings?

Meridian Bioscience's (VIVO) fiscal third-quarter results are likely to reflect strong performance by Life Science business line.

ABIOMED (ABMD) to Report Q1 Earnings: What's in the Offing?

The commercial rollout of ABIOMED's (ABMD) Impella 5.5 is expected to have progressed steadily through the fiscal first quarter.

DENTSPLY SIRONA (XRAY) to Post Q2 Earnings: What's in Store?

DENTSPLY SIRONA's (XRAY) second-quarter results are likely to reflect weak segmental performance.